The AMPLE randomized clinical trial compared an indwelling pleural catheter with talc pleurodesis in patients with symptomatic malignant pleural effusion. The primary question was whether the catheter strategy could reduce the total number of days spent in hospital over the remaining lifespan. Patients allocated to an indwelling catheter spent fewer days in hospital overall, with much of the difference coming from fewer effusion-related hospitalization days. Both approaches are established ways of managing symptomatic malignant pleural effusion, so the trial is best understood as evidence for choosing the strategy that fits the patient rather than identifying one universal winner. Factors such as expandable versus trapped lung, expected prognosis, home support, procedural burden and patient preference all matter. This aligns with the NAPCON pleural-disease session and its emphasis on practical escalation and individualized management. The trial is also relevant to palliative care because the outcome of interest was not simply pleural fluid control, but how treatment affected hospital use during advanced disease. For HCPs, the paper supports discussing outpatient drainage options as part of goal-concordant care when appropriate.